Plan B Takes Dr. Reddy’s Into Hot US Nexium Market
This article was originally published in PharmAsia News
Shares of Dr. Reddy's surged on Indian bourses after the firm announced the launch of generic Nexium (esomeprazole magnesium) delayed release capsules in the US, after implementing a super-fast site transfer for the much anticipated product.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.